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ANCA-associated-vasculitis (AAV) comprises three different
diseases entities: Churg–Strauss syndrome, microscopic
polyangiitis, and Wegener’s granulomatosis. AAV is an
autoimmune disease with complex pathophysiology.
Anti-neutrophil cytoplasmic antibodies (ANCAs) with
specificity for proteinase-3 (PR3) or myeloperoxidase (MPO)
are hallmarks of AAV and have a pivotal role in disease
development. In addition to ANCA, the cellular immune
system contributes to the pathogenesis of the disease.
ANCA-mediated degranulation of neutrophils causes
vasculitic damage; T cells drive granuloma formation,
promote vasculitic damage by several different pathways,
and enhance autoantibody production by B cells. Recently,
complementary PR3 and lysosomal membrane protein-2
were suggested as novel autoantigens in AAV. New
findings also indicate the importance of complement,
danger-associated molecular patterns, and dendritic cells
in AAV. This review highlights novel pathophysiological
findings in AAV and puts them into context with the
current understanding of disease mechanisms. Furthermore,
implications for present and new therapeutic strategies
are discussed.
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ANCA-associated vasculitis (AAV) is a life-threatening
autoimmune disease characterized by necrotizing vasculitis
of small- and medium-sized vessels.1–3 Pauci-immune
necrotizing crescentic glomerulonephritis (NCGN) is com-
monly observed.3,4 Anti-neutrophil cytoplasmic antibodies
(ANCAs) with specificity for either proteinase-3 (PR3) or
myeloperoxidase (MPO) are hallmarks of AAV. AAV
comprises three disease types: Wegener’s granulomatosis
(WG), Churg–Strauss syndrome (CSS), and microscopic
polyangiitis (MPA). The disease types differ with respect to
clinical manifestations and histological findings. Granulo-
matous inflammation is observed in WG and CSS but not in
MPA.2,5,6 Furthermore, neutrophils are abundantly found in
WG-associated inflammation, whereas in CSS eosinophils
dominate the inflammatory infiltrate.2,3 CSS and MPA are
mostly associated with ANCAs directed against MPO,
whereas WG is more associated with ANCAs with specificity
for PR3.7 The pathophysiology of AAV is complex and the
humoral as well as the cellular immune system are involved.
ANCAs themselves are thought to be pathogenic. Further-
more, ANCAs promote degranulation of neutrophils and
monocytes facilitating endothelial damage.8 The endothelium
is also activated and thereby neutrophil adherence is
enhanced.9–11 The initial damage leads to a cascade of events,
resulting in leukocyte tissue infiltration, T-cell-driven gran-
uloma formation, and further damage. This simplified view
on disease mechanisms is refined and explained in detail
further below. Recent findings on ANCAs, complement,
neutrophils, lymphocytes, and dendritic cells (DCs) demand
to confine new roles for old players in AAV. Thus, we discuss
and illustrate novel insights and the role in the current
concept of disease. This review will also highlight and further
explain implications for treatment modality.
ANCAs: MODE OF ACTION
The functional characteristics of ANCAs have been studied in
different in vitro and in vivo models providing growing
evidence for pathogenicity.12
ANCAs bind to neutrophils and endothelial cells having
differential but synergistic effects on both cell types. ANCAs
bind to membrane-bound PR3/MPO on neutrophils.12,13
This interaction with ANCAs results in activation and finally
in release of cytotoxic superoxide and serine proteases (such
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as PR3).8,14 Membrane-bound MPO/PR3 is expressed
constitutively by neutrophils and can be enhanced by pro-
inflammatory cytokines like tumor necrosis factor-a
(TNF-a) and interferon-g (IFN-g) (‘priming’).13–17 Priming
of neutrophils also enhances adhesion to endothelial cells
along with a further increase of membrane MPO/PR3
expression.18,19 Thus, degranulation occurs in close contact
with the vascular endothelium, resulting in vasculitic damage
(Figure 1). There is ongoing discussion about the role of
cytotoxic mediators in endothelial damage. A recent study by
Lu et al.20 confirmed former experimental evidence suggest-
ing that serine proteases (like PR3 and elastase) are more
important than superoxide radicals in mediating cytotoxic
damage.21 The authors showed in vitro that endothelial cell
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Figure 1 | Two pathways contributing to disease mechanisms in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis
(AAV) are depicted. (a) The ‘classic neutrophil pathway’ has been studied and confirmed by several groups. This pathway causes
necrotizing vasculitis.9 (b) We propose an additional ‘T-cell pathway’ that mainly causes granulomatous inflammation and promotes
necrotizing vasculitis. Infections are the starting point of both pathways; infections trigger priming of neutrophils (a), upregulation of
adhesion molecules on endothelial cells, and expansion of circulating effector T cells (b). Primed neutrophils show increased surface
expression of ANCA antigens and adhesion molecules. ANCA binding activates the neutrophil in the following ways: (1) enhancing vessel
wall adherence and transmigration capacity; (2) production and release of oxygen radicals, and (3) degranulation and release of enzymes
including myeloperoxidase (MPO) and proteinase-3 (PR3) (a). Transient immune complexes are formed locally by binding of ANCA to PR3/
MPO sticking to endothelial cells. Subsequently, complement is activated, which further promotes neutrophil degranulation. This all adds to
the development of necrotizing vasculitis. Whether this specific cascade is also applicable to disease pathogenesis in ANCA-negative AAV
patients remains unclear. The expanded effector memory T cells (Tems) are not sufficiently regulated by regulatory T cells (Tregs, b). This
leads to dysbalance in the homeostasis of Tregs and Tems, resulting in further release of proinflammatory cytokines promoting neutrophil
priming (a); moreover, ANCA production is enhanced by further T-cell/B-cell interaction. (c) Expanded circulating Tems migrate into target
organs such as the lungs or the kidney. Within tissues, Tems drive granuloma formation, which is considered an ‘executioner’ of tissue
destruction. Granulomas are composed of numerous cell types such as T cells, B cells, giant cells, and dendritic cells (DCs). Moreover, ANCA
production occurs in granulomas. Possibly, tertiary lymphoid organs (TLOs) are ‘local controllers’ of tissue inflammation, as induction of
Tregs is thought to take place in TLOs. Neutrophil extracellular trap (NET) formation occurs in lesions as a consequence of neutrophil
apoptosis and degranulation. DNA and serine proteases are deployed in these NETs. NET-derived products activate DCs and B cells by
sensing via Toll-like receptors (TLRs). Interferon (IFN-a) production by DCs might have an impact on local immune regulation; it has been
shown to impair Tregs in function.113 Although major efforts were made to unravel the pathogenesis of AAV, some missing links remain.
The origin of ANCA is unexplained so far. If and how genetic background, microbial agents, and/or T-cell dysregulation finally lead to the
development of ANCA needs to be investigated further. HEV, high endothelial venules; ICX, immunocomplexes.
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injury was not prevented by blocking superoxide release.
However, inhibition of serine proteases led to less endothelial
cell injury. Therefore, ANCA-induced release of proteases
seems to be the most important factor for vasculitic damage.
Nevertheless, release of reactive oxygen species enhances the
activity of serine proteases by inactivating a1-anti-trypsin,
which is a potent PR3 inhibitor.22–24 Binding of ANCAs
to endothelial cells might occur via PR3/MPO acting as
cofactors or via Fc receptors, but the exact mechanism
remains controversial.11,25–27 The interaction of ANCAs with
endothelial cells enhances expression of adhesion molecules
like E-/P-Selectin and vascular cell adhesion molecule, as
shown by several authors.10,28 Subsequently, neutrophil-
endothelial cell adherence is altered as demonstrated in flow
models. ANCAs promote firm and sticky attachment of
neutrophils to endothelial cells in these models, leading to
enhanced transmigration and damage.18,29–31
Apart from in vitro experiments, ANCA pathogenicity has
been investigated in animal models. Although animal models
proving MPO-ANCA pathogenicity are well established,
similar efforts for PR3-ANCA have not been successful so
far. Xiao et al.32 immunized MPO-knockout mice with
murine MPO and transferred anti-MPO-IgG to wild-type
and immune-deficient (RAG2–/–) mice. Wild-type and
immune-deficient mice developed NCGN, proving a patho-
genic role for MPO-ANCA. The importance of neutrophils
and the priming process with proinflammatory agents was
confirmed in this model.33,34 The current rat MPO-vasculitis
model shows a varying and inconsistent disease phenotype.
Therefore, Little et al.35 recently modified this rat model by
using adjuvants to enhance immunization, resulting in
experimental vasculitis with robust and reproducible disease
expression. Pfister et al.36 could not successfully establish a
similar model for PR3-ANCA. Wild-type mice receiving anti-
PR3-IgG did not develop glomerulonephritis or human AAV
features. Interestingly, in a recent study by Primo et al.,37
anti-PR3-induced immune responses elicited NCGN in mice
prone to autoimmunity, demonstrating that PR3 immune
responses in general can cause vasculitis and NCGN.
However, a certain genetic background predisposing to
autoimmunity seems to be indispensable.37 Hattar et al.38
confirmed the pathogenic potential of anti-PR3 antibodies in
an elegant model using isolated rat lungs. Perfusion of these
lungs with neutrophils and antibodies against PR3 but not
with control IgG resulted in edema formation resembling
acute lung injury.
In summary, there is convincing evidence from both
in vitro and in vivo experiments that ANCAs are pathogenic.
ANCAs: EXPANDING RANGE OF SUBTYPES?
In the late 1980s, it was discovered that PR3 was the main
antigen for cytoplasmic-ANCA, whereas MPO was shown to
be the antigenic target of perinuclear-ANCA in patients with
vasculitis.4,7,39–44 The range of ANCA subtypes expanded and
additional autoantigens recognized by ANCAs were found.45
Recent findings bring up a new hypothesis on the induction
of ANCAs by immune responses against Gram-positive or
Gram-negative bacteria.39,45
Pendergraft et al.46 investigated the role of complementary
peptides in WG. The authors hypothesized that the initial
immune response in WG is directed against the complemen-
tary protein PR3 (cPR3) and that anti-PR3 antibodies
evolve during a secondary anti-idiotypic immune response
(Figure 2). According to this hypothesis, antibodies forming
the humoral immune response against cPR3 would serve as
antigenic target for a secondary immune response (‘anti-
idiotypic response,’ Figure 2).47 Anti-idiotypic antibodies not
only react to anti-cPR3-antibodies but also to the sense
protein PR3. Out of 34 WG patients, 7 (20%) had detectable
antibodies against cPR3 that indeed formed idiotypic pairs
with anti-PR3 antibodies. Injection of cPR3 in mice resulted
in anti-cPR3 and anti-PR3 antibodies as predicted. Interest-
ingly, cPR3 mRNA transcripts were only found in leukocytes
from WG patients but not from healthy controls or lupus
patients. Whether these cPR3 transcripts are of exogenous or
endogenous origin remains to be solved. However, pathogens
like Staphylococcus aureus bear genetic sequences that are
complementary to the human PR3 gene, pointing to an
exogenous origin of cPR3 transcripts. Indeed, chronic nasal
carriage of S. aureus has been demonstrated to increase the
risk for disease relapse.48 Moreover, WG patients treated with
cotrimoxazole are less prone to relapse, and in some cases
even remission can be induced by applying cotrimoxazole as
monotherapy.49,50 The mechanism proposed by Pendergraft
et al.46 defines a pivotal, novel role for a specific ANCA
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Figure 2 |The principle of the anti-idiotypic response in anti-
neutrophil cytoplasmic antibody (ANCA)-associated vasculitis
(AAV). This concept suggests that proteinase-3 (PR3)–ANCA are
formed during a secondary immune response to antibodies that
have specificity for complementary PR3 (cPR3). The sense strand
of the PR3 gene codes for the corresponding sense protein PR3,
whereas the antisense strand of the PR3 gene codes for the
corresponding complementary protein cPR3. According to
Pendergraft et al.,46 an immune response against cPR3 is elicited
in AAV patients. Subsequently, antibodies with specificity for cPR3
evolve. The antigen-binding region of these antibodies mimics
epitopes of the sense protein PR3. An additional immune
response against anti-cPR3 antibodies is initiated and defined as
‘anti-idiotypic response.’ According to this concept, antibodies
against anti-cPR3 evolve throughout the disease process. These
‘anti’-anti-cPR3 antibodies bind the sense PR3 and resemble
PR3-ANCA.
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subtype but needs further confirmation. In addition, the
clinical relevance and importance to disease pathogenesis
needs to be defined and remains unclear.
Recently, Kain et al.45 reported the discovery of auto-
antibodies against lysosomal membrane protein-2 (LAMP-2)
in patients with AAV-associated NCGN. They provided
in vitro and in vivo evidence for the relevance of these
antibodies to disease pathogenesis and linked them with
infectious pathogens. Anti-LAMP-2 antibodies were only
found in patients with active ANCA-associated NCGN.
Interestingly, anti-LAMP-2 antibodies were also detectable in
several patients with NCGN lacking PR3-ANCA or MPO-
ANCA. Moreover, patients with localized AAV lacking renal
involvement were generally negative for anti-LAMP-2 as were
disease controls and healthy controls. Furthermore, Wistar
Kyoto rats injected with antibodies to LAMP-2 developed
crescentic pauci-immune glomerulonephritis. Anti-LAMP-2
crossreacted with FimH, which is part of the fimbriae of
Gram-negative pathogens. Accordingly, immunization with
FimH led to development of crescentic glomerulonephritis in
rats. Altogether, these results suggest that AAV-associated
crescentic glomerulonephritis might be triggered by bacterial
infection eliciting an immune response to a previously
unidentified, novel autoantigen. However, according to our
own published observations, disease onset or relapse of AAV is
linked to Gram-positive bacteria like S. aureus and not to
infections with Gram-negative bacteria.48,51 Thus, the findings
by Kain et al.45 need to be confirmed in other patient cohorts.
HNE (human neutrophil elastase) belongs to the chymo-
trypsin family of serine proteases. ANCAs with specificity to
HNE are rarely and infrequently detected in patients with
vasculitis.52 Importantly, HNE-ANCA might be of use for
diagnosing cocaine-induced midline destructive disease and/
or drug-induced AAV.53 Dolman et al.54 detected anti-HNE
antibodies frequently in patients developing vasculitis during
treatment with propylthiouracil. These findings were con-
firmed by others showing an association of ANCA with the
administration of antithyroid drugs.55
THE COMPLEMENT SYSTEM AND ITS ROLE IN AAV
Pauci-immunity is a hallmark of ANCA-associated vasculitis,
and deposition of immune complexes or complement factors
is considered to be absent.2 However, accumulating evidence
suggests that the complement pathway is involved in disease
pathogenesis.56–60
The complement system has a pivotal role in host defense
as well as clearance of immune complexes (Figure 3).
First evidence pointing to the complement system in AAV
came from biopsy studies already performed in the late
1970s.56 In following studies, renal and skin biopsies from
patients with AAV were assessed for complement deposi-
tions.58–68 Collectively, more than half of the biopsies from
patients with AAV were found to have C3 complement
deposition. In vitro evidence supports the idea of comple-
ment involvement in AAV. Several groups have shown that
MPO or oxygen radicals released by degranulation of
neutrophils activate complement factors C3 and C5.69–71
Moreover, Xiao et al.72 demonstrated that ANCA-induced
activation of neutrophils results in complement activation
and generation of C3a. Interestingly, complement receptors
are also present on neutrophils. Schreiber et al.73 found that
C5a is able to prime neutrophils and to enhance ANCA-
induced neutrophil activation. Therefore, neutrophils are
linked very tightly to complement activation. These in vitro
data are supplemented by in vivo data from animal models.
Huugen et al.74 could prevent and/or attenuate MPO-
induced NCGN in mice by anti-C5 treatment. Likewise,
Xiao et al.72 completely blocked development of MPO-
induced NCGN by complement depletion using cobra venom
factor. Furthermore, NCGN was absent in factor B knockout
mice (an essential factor for alternative pathway) but could
be induced in C4 knockout mice (an essential factor for
classical/lectin pathway), providing some evidence for
pathogenetic involvement of the alternative pathway of
complement activation.72 In conclusion, the complement
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Figure 3 |Overview on the complement system. The
complement system has a pivotal role in host defense as well as
clearance of immune complexes. Three different activating
pathways of the complement cascade have been identified so far.
Although the initial activating steps are different, all pathways
end up in a common, terminal pathway characterized by cleavage
of C5, which finally results in assembly of membrane attack
complex (MAC). The classical pathway is initiated by binding of
C1q to antigen–antibody complexes, enhancing the formation of
a specific C3 convertase (C4b2a). Binding of cleaved C3b to this
complex forms C5 convertase. The same convertases are activated
by the lectin pathway. In this case, Mannose-binding lectin and
ficolins bind to carbohydrates of bacterial pathogens followed by
activation of mannose-binding lectin-associated serine proteases
(MASPs). These MASPs cleave C4/C2 to the above-mentioned C3
convertase and subsequent C5 convertase activation. The
alternative pathway is activated by a different
C3 convertase (C3bBb). This C3 convertase is formed by C3
hydrolyzing spontaneously and is stabilized by factors B and D. By
further association of C3b to this complex, C5 cleaving convertase
(C3bBbC3b) is formed.
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system seems to be an important player in AAV. Complement
activation and the resulting products might promote
inflammation and enhance tissue damage. Although the
exact mechanisms are not known yet, the neutrophil–com-
plement axis might be crucial. Neutrophils become activated
by complement products and complement is activated by
neutrophils. Hence, dysregulation of this axis might lead to
sustained, self-perpetuating inflammation and contribute in
this way to AAV (Figure 1). Finally, complement activation
might also account for increased risk of venous thromboem-
bolism observed in active AAV, as activated complement
factors trigger coagulation.75,76
T CELLS IN AAV
T cells are usually found within granulomas as well as in
other lesions present in AAV.77–80 In accordance with these
findings, elevated levels of markers of T-cell activity such as
soluble interleukin-2 (IL-2) receptor, neopterin, and soluble
CD30 as measured in the circulation have been shown to be
associated with disease activity.81–83 Furthermore, ANCA IgG
subclasses suggest that a T-cell-mediated subclass switch has
taken place.84 Specific T-cell-targeted therapy is occasionally
used in refractory cases and has been demonstrated to be
beneficial.85
In patients with active disease and during remission,
T cells are in a persistent state of activation.81 Furthermore,
memory T cells are expanded, whereas naive T cells are
decreased.86,87 Recently, we demonstrated that a specific
subset of effector memory T cells (Tems) expressing CD134
and GITR (glucocorticoid-induced TNF-receptor-related
protein) is especially expanded in WG patients.88 CD134þ
cells were also found in active lesions, suggesting increased
migration to inflamed sites (Figure 1). In line with this,
Abdulahad et al.89 reported Tems in the urine, suggesting that
Tems migrate from the circulation to inflammatory lesions
during active states of the disease. Tems are powerful immune
cells that initiate and sustain immune responses. This T-cell
population is long lived and responds quickly to adequate
triggers. Moreover, granuloma formation is driven by these
T cells.90 Therefore, we believe that Tems have a major
pathophysiological role in AAV.
IL-17-producing Th17 effector T cells were shown to be of
major importance in autoimmunity.91 Recently, it was
reported that WG patients in remission bear an increased
amount of Th17 cells reactive to the autoantigen PR3.92,93
Moreover, AAV patients harbor an expanded CD45RC
T helper cell population that is a source of IL-17.94 IL-17
facilitates the migration and activation of neutrophils by
promoting the secretion of TNF-a and IL-1b.95 As the influx
of neutrophils is a hallmark of AAV, IL-17 might also have a
pivotal pathophysiological role in AAV.
Regulatory T cells (Tregs) limit immune responses. In
some autoimmune diseases, Treg defects have been des-
cribed.96 There are limited data on Tregs in AAV. However, an
increase of FoxP3þ Tregs in patients with AAV in remission
was described in one study, whereas earlier studies failed to
show an increase of circulating FoxP3þ Tregs.86,97 Subse-
quently, two studies suggest a functional impairment of Tregs
in WG.98,99 These Tregs fail to inhibit proliferation or
cytokine production of effector T cells. Defective Treg
function might account for the Tem expansion and the
persistent T-cell activation observed in AAV (Figure 1).
TERTIARY LYMPHOID TISSUE IN AAV
At present, it is unknown whether local activation or control
of the immune response within the affected tissue itself
occurs in AAV. Local control of immune responses is linked
to the development of tertiary lymphoid organs (TLOs), also
known as lymphoid neogenesis.100 This has been described
in several chronic inflammatory conditions, for example,
rejection in the context of organ transplantation and/or
inflammation in the context of several autoimmune dis-
eases.100 TLOs resemble the structure of secondary lymphoid
organs and consist of B-cell follicles with a surrounding
mantle zone with T cells and DCs. Within these TLOs, T-cell
activation by antigen-presenting cell stimulation takes place.
It is likely that local, tissue-specific (auto) antigens are
presented. Whereas secondary lymphoid organs have orga-
nized lymph flow and antigen-presenting cell trafficking,
TLOs lack these features, resulting in an unrestricted access of
antigens, antigen-presenting cells, and lymphocytes. These
conditions might promote persistent and non-physiological
T-cell activation in autoimmunity.100
What is the evidence for TLOs in AAV? So far, granulomas
are regarded as some form of TLOs where immune responses
are modified.78,101 First, Csernok et al.102 revealed that PR3 is
abundantly present in granulomas and renders DCs to
powerful Th1-cell activators. Indeed, Muller et al.103 found
mature DCs in granulomatous lesions of nose biopsies.
Moreover, Voswinkel et al.104 demonstrated that affinity
maturation of B cells, as is commonly observed in lymphoid
tissue, takes place in granulomas. It is suggested that the
production of ANCA takes place locally within these
granulomas.
Granuloma formation is only rarely found in the kidneys
of AAV patients. Some form of lymphoid neogenesis,
however, has been observed in renal biopsies of patients
with AAV.105–107 Immature DCs and T cells form aggregates,
suggesting a cell–cell interaction. Importantly, these DCs
display costimulatory capability by expressing CD80.106 We
hypothesize that in the kidney also, activation of effector
T cells and stimulation of the immune response takes place.
However, a local induction of Tregs and thus an attenuation
of the inflammatory process seems to be another possibi-
lity.106,108 Our own data indicate that FoxP3þ T cells are
present in inflammatory lesions of NCGN (B Wilde and
JW Cohen Tervaert, unpublished data, 2009). The induction
of Tregs is especially confined to places where abundant
immature DCs bearing costimulatory properties are pre-
sent.109 Recently, Kessenbrock et al.110 added an important
piece of the puzzle. They reported formation and renal
deposition of neutrophil extracellular traps (NETs) in
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AAV. NETs are decondensed chromatin fibers released by
neutrophils that contain several cytoplasmic proteins like
PR3, MPO, elastase, and LL-37. NET formation is a
mechanism of host defense and allows efficient containment
as well as killing of microbial invaders.111 However, NET
formation also exerts immune-modulating functions with
implications for autoimmunity and AAV. LL-37 deployed in
NETs is capable of modifying trapped DNA. The modified
DNA then acts as a danger-associated molecular pattern and
activates DCs and B cells via Toll-like receptor (TLR)-sensing
pathways.112 In AAV, renal NET deposition triggers IFN-a
production of plasmacytoid DCs.110 IFN-a might sustain
inflammation by impairing lesional Tregs in their func-
tion.113 Furthermore, local B-cell maturation and autoanti-
body production might result from excessive Toll-like
receptor triggering.114 Indeed, Steinmetz et al.107 reported
highly complex B-cell follicles suggestive of organized TLOs
in renal tissue of AAV patients.
Therefore, both local control of tissue inflammation and
activation of immune cells at the site of inflammation are
likely to occur in AAV (Figure 1).
DISEASE PATHOGENESIS AND CURRENT THERAPEUTIC
CONCEPTS
Summarizing the preceding paragraphs, disease pathogenesis
of AAV is complex with a number of overlapping effector
limbs. It is clear that ANCAs are of major importance for
disease and cause vasculitis, interacting with neutrophils
upon specific triggers like infections (Figure 1). At the same
time, Tems escaping immune regulation enhance autoanti-
body production and drive tissue inflammation (Figure 1).
Interfering with these pathogenic mechanisms is crucial, as
the patients’ outcome is fatal if the disease is left untreated.115
The outcome has improved dramatically since the introduc-
tion of cyclophosphamide (CYC) as a therapeutic agent of
AAV.115,116 Most of the drugs used for treatment have a broad
spectrum of activity affecting all effector limbs. CYC is one of
the most efficient agents available to treat AAV and targets a
number of mechanisms described above. It alkylates DNA
and thus affects a wide variety of cell types including
leukocytes that lack aldehyde dehydrogenase, an essential
enzyme breaking down the toxic metabolite of CYC.117 Thus,
B-cell suppression is usually observed and T cells as well as
neutrophils are hit by CYC treatment.118 This results in
reduction of pathogenic ANCAs, fewer pathogenic effector
memory T cells, and less neutrophils. Azathioprine (AZA),
methotrexate (MTX), and mycophenolate mofetile (MMF)
interfere with DNA or nucleotide synthesis, affecting dividing
cells and thus also pathogenic lymphocytes. Some of the
knowledge gained on the pathogenesis of AAV has already
been translated into new and specific therapeutic approaches
with presumably less side effects. Plasmapheresis and B-cell
depletion using rituximab (RTX) are both applied success-
fully in treating AAV and have the rationale to ameliorate
disease by removing autoantibodies or their source.119–122
Specific T-cell depletion with agents like antithymocyte
globulin or Campath-1H (CAMP) has also already been
introduced into the clinic but the efficacy is limited so
far;85,123 see Figure 4.
CURRENT THERAPY OF ANCA-ASSOCIATED
VASCULITIS: THE EULAR GUIDELINES
Recently, guidelines on treatment made by a working group
of the EULAR (European League Against Rheumatism) were
published based on data of recent studies.124 During the
initial phase, remission is induced (‘induction phase’),
whereas thereafter remission is maintained (‘maintenance
therapy’). The pharmacotherapy of both phases is different.
The most effective and best evaluated drug used in the
induction phase is CYC. However, it is toxic in a dose-
dependent manner and associated with severe side effects
affecting long-term morbidity as well as mortality.125 High
cumulative doses above 36 g seem to increase the risk for
leukemia and bladder cancer.125 Thus, adjustment of
treatment to disease severity has been suggested (Tables 1
and 2).124 The disease category reflects the disease extent
(Table 1). In case of severe generalized disease, CYC and
glucocorticoids (prednisolone (PRED)) in combination
are recommended for induction of remission. Oral versus
intravenous (i.v.) administration of CYC was studied in the
CYCLOPS study by the EUVAS group. Periodical i.v. infusion
reduces the cumulative CYC dosage needed and thus toxicity;
long-term morbidity and/or mortality because of CYC might
be lower.126 In the randomized controlled trial (RCT)
CYCLOPS, a total of 149 WG/MPA patients suffering from
new-onset generalized AAV were enrolled: 76 patients were
assigned to the i.v. CYC group and 73 were randomized to
the oral CYC group. It was seen that 88.1% of the i.v. CYC
group and 87.7% of the oral CYC group achieved remission
after 9 months. There was no significant difference in median
time to remission (3 months each) or improvement of renal
function at study end. Although not statistically significant,
more relapses occurred in the i.v. CYC group (n¼ 13) than in
the oral CYC group (n¼ 6). As expected, the cumulative CYC
dosage needed to achieve remission was significantly lower in
the i.v. CYC group as opposed to the oral CYC group (8.2 vs
15.9 g, Po0.001). Furthermore, less patients were affected by
leucopenia in the i.v. CYC group when compared with the
oral CYC group (26 vs 45%, P¼ 0.016). Toxicity as observed
during a period of 18 months did not differ. In summary, i.v.
CYC seems to be as efficient as oral CYC in inducing
remission.126 The safety profile with possible decreased long-
term toxicity because of low CYC doses favors i.v. CYC
therapy over oral CYC. The oral CYC regime used
in CYCLOPS differed from other studies. In the RAVE and
the CYCAZAREM trial, oral CYC was administered for
3 months, and beyond that only until remission was
achieved.121,127 Oral CYC was ceased immediately after
having entered remission and then replaced by maintenance
therapy. However, in the CYCLOPS trial, oral CYC was not
ceased after remission had been achieved but continued for
additional 3 months (at a reduced dose of 1.5 mg/kg/day).126
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This might also account for the large difference in the median
cumulative dose between oral and i.v. CYC observed in
CYCLOPS. Furthermore, it is not yet clear whether i.v. cycles
result in a higher relapse rate. A recent meta-analysis points
at an increased risk of relapse in patients treated with i.v. CYC
when compared with oral CYC (four studies, relative risk
1.79, confidence interval 1.11–2.87, P¼ 0.02).128 There was
no difference in mortality or remission rates.128 Nonetheless,
a switch to oral CYC should be considered if induction
therapy with i.v. CYC fails, and during the last year we
observed several i.v. CYC failures (JW Cohen Tervaert,
personal observation, 2009).
Removing circulating ANCA might be beneficial con-
sidering the pathogenic potential of these autoantibodies.
Principle Mechanism Agent Evidence References
Migration
inhibitor
Kill bacteria
Interfere
with granuloma
formation
Inhibit B-cell
maturation
Deplete
B cells
Depletion of effector
T cells
Regulation of effector
T cells
Block adhesion of
neutrophils
Limit activation/
recruitment of neutrophils
Enhance vascular repair
Inhibition of migration
Interfere with granuloma
formation
Depletion of B cells
Inhibition of B-cell
maturation
Anti-microbial treatment
Antibodies directed against
CD25 deplete activated T cells
Blockade of CD28/CD80
dependent T cell activation
Blockade of CD11b/ICAM-1
mediated adhesion to endothelium
Inhibition of C5 cleavage. Blockade
of C5a receptor on neutrophils
Promote EPC mobilization
and function
Blockade of TNF-α
Blockade of a4-integrins 
on T cells
B-cell depletion by antibodies
recognizing CD20/CD22
Neutralization of BLys. Blockade of
BLys-receptors on B cells
Reduction of microbial flora that
might trigger disease flares
Basiliximab
Daclizumab
Block adhesion
limit activationDepletion/
regulation of
effector
T cells
Enhance
vascular
repair
Abatacept, Belatacept
(both CTLA-4 fusion
proteins)
Belimumab (anti-BLys)
Atacicept (anti-TACI)
Experimental + clinical
evidence in AAV
Experimental + clinical
evidence in AAV
Experimental + clinical
evidence in MS
Experimental +
clinical evidence
Experimental + clinical
evidence in AAV
Experimental
evidence
Experimental
evidence
Experimental
evidence
Rituximab, Epratuzumab
(both anti-CD20)
118–122, 166, 177
118–122, 166, 177
Eculizumab, Pexelizumab
(both anti-C5)
EPO
Statins
Natalizumab
Infliximab
Adalimumab
Cotrimoxazol 45, 48–51
90, 134–136
169, 170
173–176
179, 180
73, 74
18,178
NCT0040248
NCT00468208
172
Experimental + clinical 
evidence (RA+Tx)
Ongoing RCT in AAV
Experimental + clinical 
evidence (RA+Tx)
Ongoing trial in AAV
S, aureus
EPC
Figure 4 |Understanding the pathogenesis of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) allows
application of targeted therapy. As autoantibodies have a key role in AAV, depletion of B cells or interfering with maturation of these cells
might ameliorate disease.177 Blocking adhesion and activation of neutrophils might also dampen or even prevent vasculitic damage.178
Vasculitic damage needs to be repaired and endothelial progenitor cells (EPCs) are regarded as an important factor of vascular repair. EPC
mobilization and function might be enhanced by additional treatment with erythropoietin (EPO) or statins. T cells drive the disease
as well and could be targeted. For this purpose, T-cell activation could be limited by interfering with the costimulatory molecules and it
might be beneficial to deplete subsets of effector T cells.179,180 Next, migration of T cells to tissue sites or T-cell-driven granuloma formation
might be inhibited by biologics already available. Finally, treatment with antibiotics might prevent disease flares triggered by
bacteria.48,49,181 BLys, B lymphocyte stimulator; CTLA-4, cytotoxic T-lymphocyte antigen 4; ICAM-1, intercellular adhesion molecule 1; MS,
multiple sclerosis; RA, rheumatoid arthritis; RCT, randomized controlled trial; TNF-a, tumor necrosis factor-a. TACI, transmembrane activator
and calcium-modulator and cyclophilin ligand interactor.
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The RCT MEPEX assessed the impact of plasmapheresis on
renal/patient survival in a cohort of WG/MPA patients with
severe renal vasculitis and acute renal failure.120 Adjunct
plasmapheresis in combination with oral CYC/PRED im-
proved renal recovery when compared with the control arm
receiving concomitant courses of i.v. methylprednisolone
instead of plasmapheresis. At 3 months, 69% of the AAV
patients in the plasmapheresis group were alive and
independent of dialysis as opposed to 49% in the control
arm. Furthermore, plasmapheresis was associated with a
reduction in the risk of progression to end-stage renal disease
at 12 months (24%, confidence interval 6.1–41%).There was
no difference in patient survival or adverse event rate.120 A
recent meta-analysis by Walters et al.128 confirmed these
results in showing that adjunct plasma exchange reduces the
risk of requiring dialysis 12 months after induction treatment
(Five studies, relative risk 0.47, confidence interval 0.3–0.75,
P¼ 0.002). Based on these findings, adjunct plasma exchange
is advised in patients with severe renal involvement, alveolar
hemorrhage, or other life-threatening organ manifesta-
tions.120 A large RCT (‘PEXIVAS’) is currently underway to
assess the impact of plasma exchange on mortality and renal
survival in both MPO/PR3 patients with estimated glomer-
ular filtration rate o50 ml/min per 1.73 m2.129 If AAV is
present without kidney involvement (defined as serum
creatinine o120 umol/l), MTX can be used in combination
with PRED to spare CYC and to reduce unwanted toxic side
effects.130 In the NORAM study (RCT) enrolling WG/MPA
patients, it was demonstrated that MTX was not inferior to
CYC/PRED in inducing remission at month 6. However,
remission was significantly delayed in patients with extensive
disease and pulmonary involvement when treated with MTX.
Furthermore, there were more relapses in the MTX limb
when compared with the CYC/PRED limb.130
INDUCTION THERAPY IN AAV: ALTERNATIVE STRATEGIES
MMF has also been assessed for induction of remission in
two open label trials and in a retrospective case review
study.131–133 Complete and partial remission could be
achieved in a substantial number of patients by MMF
administration. Additional RCTs are needed to answer
questions regarding efficacy.131–133 RTX has recently been
studied as an alternative to the standard induction protocol
with CYC. Two RCTs provide evidence that RTX/PRED is
noninferior to CYC/PRED induction therapy.119,121 The
placebo-controlled RAVE study enrolled 197 patients with
MPA/WG and consisted of two trial arms, in which induction
therapy with oral CYC/PRED (n¼ 99) was compared with
RTX/PRED (n¼ 98, 4 times 375 mg/m2).121 A total of 55% of
patients in the CYC arm and 64% in the RTX arm achieved
complete remission and were off PRED after 6 months
(P¼ 0.21). There was no difference in the rate of adverse
events or relapses within the first 6 months for patients with
new-onset disease, whereas in patients with relapsing disease
RTX was significantly better than CYC. A different RCT
organized by the EUVAS group (‘RITUXVAS’) compared the
standard CYC induction protocol to RTX in patients with
severe generalized WG/MPA.119 These patients were suffering
from more severe disease as indicated by a median
glomerular filtration rate of 18 ml/min per 1.73 m2. Patients
were either treated with 6–10 cycles of CYC pulses or with
RTX (4 times 375 mg/m2) in combination with two pulses of
Table 1 | Disease categories as defined by the European League Against Rheumatism124
Disease category Definition
Localized Upper and/or lower respiratory tract disease without any other systemic involvement or constitutional symptoms
Early systemic Any, without organ- or life-threatening disease
Generalized Organ-threatening disease, if renal involvement: serum creatinine o5.6mg/dl
Severe Vital organ failure, if renal involvement: serum creatinine 45.6mg/dl
Refractory Disease progression despite therapy with cyclophosphamide and steroids
Table 2 | Recommendations for therapy of AAV by the European League Against Rheumatism124
Disease category Recommended therapy Grade of recommendationa Level of evidenceb
Remission induction
Early systemic/localized disease Methotrexate+steroids B 1B
Generalized disease Cyclophosphamide (i.v. or oral)+steroids A 1AWG/MPA
1BCSS
Severe disease with renal failure Adjunct: plasma exchange A 1B
Maintenance therapy
Low-dose steroids + Azathioprine A 1B
Leflunomide B 1B
Methotrexate B 2B
Abbreviations: ANCA-associated vasculitis; CSS, Churg–Strauss syndrome; i.v., intravenous; MPA, microscopic polyangiitis; RCT, randomized controlled trial; WG, Wegener’s
granulomatosis.
aGrade of recommendation: A, based on at least evidence level 1A/B; B, based on at least level 2 evidence or extrapolated recommendations from level 1 evidence.
bLevels of evidence: 1A, evidence from meta-analysis of RCT; 1B, from at least one RCT; 2B, from at least one type of quasi-experimental study.
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CYC. Maintenance therapy with AZA was only given to
patients in the CYC group, and the RTX group did
not receive maintenance therapy. A total of 44 patients
were enrolled: 33 in the RTX group and 11 in the CYC group.
The outcome was comparable in both groups; 76% of
patients in the RTX group and 82% of the patients in the
CYC arm had entered sustained remission after 12 months
(P¼ 0.67). The improvement of renal function during
therapy was not different as was the rate of adverse events.
These studies provide good evidence for noninferiority of
RTX when compared with CYC to induce remission without
the burden of long-term toxicity. However, there are not
sufficient data on long-term outcome in AAV available yet.
There is a controversy on the use of TNF-a blockade in
treatment of AAV. Etanercept was assessed in the WGET trial
and serious concerns on safety were raised, as the incidence
of malignancies was higher in WG patients treated with
etanercept.134,135 Although this TNF-a blocker has no place
in the therapy of AAV, other agents like infliximab or
adalimumab are still under evaluation for therapy. The
efficacy of adalimumab, which is a humanized anti-TNF-a
antibody, was recently studied by Laurino et al.136 in a
prospective, uncontrolled phase II trial. A total of 14 patients
with new-onset systemic WG/MPA and kidney involvement
were enrolled. Adalimumab was administered concomitantly
with CYC and PRED, and 79% of all patients entered
remission within the first 3 months. Adalimumab adminis-
tration permitted lower prednisone dosages during the first 3
months when compared with standard induction proto-
cols.136 Interestingly, CSS patients lacking poor prognosis
factors like renal impairment, cardiomyopathy, severe
gastrointestinal tract, or central nervous system involvement
respond to single treatment with steroids and enter remission
as shown by Ribi et al.137 in a prospective, randomized open-
label trial. As relapses were common and occurred in 35% of
the patients, the efficacy of this approach is clearly limited.
Combination with AZA, MMF, or MTX might allow
sustained remission if first-line therapy with CYC/PRED is
considered to be too toxic.137,138
INDUCTION THERAPY: REFRACTORY PATIENTS
There are additional options for induction therapy in
patients refractory to standard protocols (Figure 4). Intrave-
nous immunoglobulins were shown in one randomized trial
to reduce disease activity of WG/MPA patients.139 However,
the effects were small and short lived, as beyond 3 months
there was no additional benefit when compared with placebo
infusions. 15-Deoxyspergualin was tested in uncontrolled
open-label studies in WG patients with refractory, persistent
disease activity.140,141 In 95%141 and 70%140 of these patients,
at least partial remission was achieved. Further follow-up
data suggest that prolonged treatment with 15-deoxysper-
gualin is necessary to maintain remission, as relapses were
common after withdrawal. A new phase III trial is currently
in preparation to further assess the therapeutic value of
15-deoxyspergualin. T-cell-targeted treatment with antithy-
mocyte globulin is also reported to be beneficial in selected
patients with severe, refractory WG.85 Another T-cell-
depleting agent, CAMP, has been studied by Walsh et al.123
CAMP is a humanized antibody against CD52 present on
lymphocytes and macrophages. This cohort study by Walsh
et al.123 on CAMP treatment in AAV patients with refractory
or relapsing disease showed high mortality, with
31 deaths out of 71 AAV patients. In all, 60 (85%) patients
entered remission but 43 relapsed within a median time of
9.2 months. Adverse events like infections (n¼ 28), thyroid
disease (n¼ 8), and malignancies (n¼ 3) were common.
Infections or a combination of infection and active disease
were the cause of death in 12 cases. Given the mortality and
the risk of infection observed in this study, the use of CAMP
should be considered carefully and should be restricted to a
selected cohort of refractory patients.123 In selected cases with
refractory and/or severe disease, allogeneic hematopoietic
stem cell transplantation might allow control of disease
activity as recently reported by Bornhauser et al.142 Ad-
ditionally, two retrospective studies suggest that RTX might
be efficient to induce remission in patients with refractory
AAV.143,144 There is one uncontrolled, prospective open-label
trial that assessed the value of IFN-a treatment in seven CSS
patients refractory to standard therapy.145 These patients
received IFN-a for 6 months along with steroids. Five
patients entered complete remission, whereas two were
reported to have residual symptoms. No relapses or serious
adverse events occurred during 6 months of follow-up. Thus,
IFN-a appears to be an option in selected refractory cases;
however, because of the small sample size and short follow-
up, no certain conclusion on efficacy or safety can be
drawn.145 Furthermore, biologicals like mepolizumab, an
anti-IL-5 antibody, and omelizumab, an anti-IgE antibody,
might allow induction of remission in refractory CSS. Yet,
there are only series of case reports published and evidence is
based on only a few patients.146,147
MAINTENANCE THERAPY IN AAV
Maintenance therapy should follow induction therapy as
relapses frequently occur in AAV patients.148 Some authors
stress that there might be a subset of patients with distinct
clinical features not requiring long-term maintenance ther-
apy.149 This subset of patients is characterized by the presence
of MPO-ANCA and vasculitis without involvement of
respiratory tract, but specific markers allowing reliable
identification are missing so far.149,150 Thus, at present, we
advise to continue maintenance therapy for at least 18–24
months as recommended by the EULAR and the British Society
for Rheumatology.124 Owing to long-term toxicity, CYC should
not be used anymore for maintenance of remission, as AZA was
proven to be as effective as CYC in preventing relapses of WG/
MPA patients.127 MMF was studied in a number of smaller
studies and the efficacy was varying.131,151,152 A large RCT
(IMPROVE) comparing AZA with MMF conducted by the
EUVAS study group was recently performed and preliminary
results show inferiority of MMF.153
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MTX might be considered as an alternative to AZA. In a
RCT, however, there was a nonsignificant trend to more
severe side effects with MTX when compared with AZA.154
Leflunomide (LEF) was compared with MTX in a controlled
trial by Metzler et al.155 This trial had to be terminated early
as the rate of major relapses in the MTX limb was too high
(46%). However, the relapse rate in the LEF limb (13.1/100
patient-years) was comparable with the one observed for
AZA in the CYCAZAREM trial (10.3/100 patient-years),
indicating the efficacy of LEF as a therapeutic agent in
AAV.127,155 Importantly, the LEF-associated adverse events
are problematic, especially hepatotoxicity with subsequent
organ failure.156 Low-dose PRED should be added to
maintenance therapy. The duration is, however, debatable.
A meta-analysis found a decreased proportion of relapsing
patients in studies with long-term steroid treatment (14%) as
opposed to studies with withdrawal of steroids (43%).157 As
relapses are associated with nasal carriage of S. aureus,
antibiotics might be useful in preventing disease flares.48
Cotrimoxazole treatment decreases the incidence of relapses
in patients with WG and is therefore advised in patients with
high relapse rates.49,51 There are few studies on maintenance
treatment in cohorts of CSS patients. Metzler et al.158
conducted a prospective, uncontrolled study to assess the
efficacy of IFN-a in maintenance of remission. A total of
13 patients received IFN-a along with steroids. Of these
patients, ten relapsed after a median time of 17 months, and
adverse events like infectious episodes (n¼ 18) occurred
frequently. Therefore, IFN-a cannot be considered as a
therapeutic option for maintenance therapy in CSS patients.
Mepolizumab, an anti-IL-5 antibody, might arise as an
adjunct therapeutic agent to spare steroids in CSS, but
evidence is little until now.159
The time point at which therapy should be adjusted (for
example switching from induction to maintenance treat-
ment) is not well defined. In most studies, induction therapy
is switched after ‘clinical remission,’ defined as the absence of
clinical symptoms attributable to active vasculitis.160,161
Interestingly, we demonstrated that switching to AZA
maintenance therapy in patients in clinical remission with a
positive PR3-ANCA titer is associated with significantly
higher relapse rates when compared with patients being PR3-
ANCA negative at the time of switch.162 Hence, ANCA levels
at the time of switch should be studied as a guideline for
treatment. Relapses, generally, are treated when clinical
symptoms occur. Ideally, biomarkers indicating disease flares
before clinical onset should be searched. As a rise in ANCA
levels often precedes disease flares,40,163 we performed more
than two decades ago a prospective, randomized, and
controlled trial to study a pre-emptive treatment strategy
based on 9 months of CYC with a short course of steroids in
patients after an ANCA rise.164 Our study indicated that pre-
emptive strategies based on monitoring biomarkers might be
used in reducing relapse rates. As our study was done with
CYC and as it is considered to be too toxic to be used for this
purpose, we do not recommend its use as a pre-emptive
therapy.165 Other therapies such as RTX should be studied
for relapse prevention based on ANCA levels.166 Alternatively,
other biomarkers should be considered to predict relapses.
Monitoring Treg/Tem ratio might be of interest for this
purpose. In the field of transplant immunology, ratios
between Tregs and Tems are regarded to be important for
establishing and maintaining tolerance.167 One study assessed
the value of these ratios in predicting significant episodes of
rejection after a kidney transplant.168 It was demonstrated
that episodes of rejection were preceded by a shift from Tregs
to Tems. One could speculate that these ratios are also skewed
toward Tems in WG, especially in case of a relapse. However,
this has not been investigated in a prospective study at
present.
In conclusion, therapy of AAV should be adapted to the
phase and severity of disease. For induction therapy of
generalized and severe disease, CYC therapy with steroids
should be the first choice and plasmapheresis should be
considered in cases with renal failure and/or life-threatening
disease (Table 2). Alternatively, RTX might be used if CYC is
contraindicated. Otherwise, less toxic drugs such as MTX or
MMF can be used in systemic disease that is not life
threatening. To maintain remission, CYC should be replaced
by AZA, MMF, MTX, or LEF.
FUTURE THERAPEUTIC CONCEPTS
Future therapeutic strategies should target specific disease
mechanism possibly with reduced toxicity. As depicted above,
T cells and T-cell migration are pivotal in AAV pathogenesis.
Therefore, blocking T-cell adhesion to endothelial cells
and interfering with T-cell trafficking might be beneficial
(Figure 4). This approach is currently assessed by using
natalizumab in patients suffering from multiple sclerosis.169
However, the safety profile does not seem to be as good as
was hoped, as an increased incidence of multifocal leukoen-
cephalopathy was reported during therapy.169,170 Another
option might be cell-based therapy to modulate T-cell
activity (Figure 4). Treg expansion might help to counter-
balance persistent T-cell activation in AAV. However, such an
approach is very labor intensive and might not be safe, as
recent experimental studies revealed that Tregs are able to
convert to effector T cells under certain, currently unknown
circumstances.171 In addition, control of T-cell activation
might be an attractive therapeutic option. In this regard,
blockade of costimulatory pathways such as CD28/CD80 has
successfully been used in rheumatoid arthritis and might be a
therapeutic opportunity in AAV.172 Also, ‘new players’ in the
field such as the complement factor C5 and its receptor might
be studied as targets for future therapy.73,74 Repair of vascular
damage is an additional critical point that needs to be
considered for upcoming therapeutic options. Vascular repair
is thought to be mediated by endothelial progenitor cells
(EPCs) present in the circulation.173 AAV is associated with
increased cardiovascular morbidity and it has already been
demonstrated that AAV patients bear a lower frequency of
EPCs than healthy controls.174–176 Moreover, low amounts of
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circulating EPCs seem to increase the probability of disease
flares.175 Thus, promoting EPC mobilization and function
might have beneficial impact on disease course (Figure 4).
Common drugs like statins and angiotensin receptor blockers
enhance EPC mobilization and should be used as an
adjunctive therapy in patients with AAV because of the risk
of accelerated atherosclerosis.176 In addition, erythropoietin
is able to enhance EPC function and should be studied in
AAV.173 In conclusion, there are several promising candidates
that will amend the therapy of AAV in future. This will
hopefully lead to improved prognosis and result in less toxic
therapeutic regimen.
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